Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Fujifilm Kyowa Kirin, Mylan Bag EU Approval of Humira Biosimilar
Fujifilm Kyowa Kirin Biologics and Mylan said on September 20 that the European Commission gave its thumbs up to Hulio, their biosimilar version of the TNF-α monoclonal antibody Humira (adalimumab).The biosimilar carries the same indications as the originator. Mylan plans…
To read the full story
Related Article
- Japan’s First Humira Biosimilar Could Hit Market as Early as November
May 15, 2020
- Humira Biosimilar Grabs European Panel Backing: Fujifilm Kyowa Kirin/Mylan
July 31, 2018
- Mylan Gets EU Rights for Fujifilm Kyowa Kirin Biologics’ Humira Biosimilar
April 12, 2018
- EMA Accepts Application for Fujifilm Kyowa Kirin’s Humira Biosimilar
May 23, 2017
BUSINESS
- Fuji Curbs Shipments of Simponi, Ranmark Biosimilars Soon after Launch
September 4, 2026
- Leqembi Subcutaneous Autoinjector Approved in China
September 4, 2026
- Nxera Gets US$8.6 Million OX2R Milestone from Centessa
September 4, 2026
- Top Medipal Shareholder Seeks CEO Ouster, Special Dividend
September 4, 2026
- Nipro Grabs Japan Approval for Stelara IV Biosimilar
September 4, 2026
Japan has entered a third straight year of wage hikes averaging 5%, but the pharmaceutical industry is struggling to keep…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…